IMMUNE-MEDIATED MYELITIS

This adverse event was reported 26 times

These drugs are most commonly taken by patients reporting IMMUNE-MEDIATED MYELITIS:

# Drug Count
0 PEMBROLIZUMAB 11
1 NIVOLUMAB 8
2 IPILIMUMAB 7
3 CISPLATIN 3
4 INFLIXIMAB 3
5 LENVATINIB 3
6 VONOPRAZAN FUMARATE 3
7 ACETAMINOPHEN 2
8 ACETAMINOPHEN 500MG 2
9 ACETAMINOPHEN TABLET EXTENDED RELEASE 2
See all common drugs associated with IMMUNE-MEDIATED MYELITIS

IMMUNE-MEDIATED MYELITIS is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 OBECABTAGENE AUTOLEUCEL 1 0.0141
1 VONOPRAZAN FUMARATE 3 0.0004
2 HYDROCORTISONE SODIUM SUCCINATE 1 0.0003
3 PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF 1 0.0002
4 IPILIMUMAB 7 0.0002
5 CILTACABTAGENE AUTOLEUCEL 1 0.0002
6 PEMBROLIZUMAB 11 0.0001
7 LENVATINIB 3 0.0001
8 VEMURAFENIB 1 0.0001
9 NIVOLUMAB 8 0.0001
See all drugs enriched for association with IMMUNE-MEDIATED MYELITIS